Below are the titles for a number of ECOG-ACRIN-related analyses published since our last Research Round-Up post in August 2023. Click on the shortened citation to access the publication.

• Breast Cancer – Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112. Ballinger TJ. J Natl Compr Canc Netw. September 2023
• Breast Cancer – Adjuvant Platinum versus Capecitabine for Residual, Invasive, Triple-Negative Breast Cancer: Patient-Reported Outcomes in ECOG-ACRIN EA1131. Smith KL. Cancer. January 2024
• Breast Cancer – The Association between Relationship Satisfaction Concordance and Breast Cancer Survivors' Physical and Psychosocial Well-Being. Vachon EA. Healthcare. January 2024
• Financial Toxicity – Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer. Kircher SM. JAMA Netw Open. January 2024
• Head and Neck Cancer – A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305. Argiris A. Eur J Cancer. December 2023
• Kidney Cancer – Localised Non-Metastatic Sarcomatoid Renal Cell Carcinoma: A 31 Year Externally Verified Study. Blum KA. BJU Int. August 2023
• Kidney Cancer – Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. Carthon BC. Clin Genitourin Cancer. October 2023
• Lung Cancer Screening – Utilization of Diagnostic Procedures After Lung Cancer Screening in the National Lung Screening Trial. Lin M. J Am Coll Radiol. October 2023
• Lymphoma – Long-Term Follow-Up of the RESORT Study E4402: A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low–Tumor Burden Follicular Lymphoma. Kahl BS. J Clin Oncol. January 2024
• Myelodysplastic Neoplasms – Discordant Pathologic Diagnoses of Myelodysplastic Neoplasms and their Implications for Registries and Therapies. Gorak EJ. Blood Advances. October 2023
• NCI-MATCH – Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN EAY131 Trial Subprotocol E. Chen MF. JCO Precis Oncol. August 2023
• NCI-MATCH – Activity of Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results of the NCI-MATCH Trial EAY131 Subprotocol J. Connolly RM. Clin Cancer Res. March 2024
• Precision Medicine – The New NCI Precision Medicine Trials. Harris LN. Clin Cancer Res. December 2023
• Smoking Cessation – The Effect of Neighborhood Socioeconomic Disadvantage on Smoking Status, Quit Attempts, and Receipt of Cessation Support Among Adults with Cancer: Results from Nine ECOG-ACRIN Cancer Research Group Trials. Walter AW. Cancer. October 2023
• Symptom Science and Treatment Toxicity – Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. O'Connell N. J Clin Oncol. October 2023
  • Editorial – Patient Experience, Adverse Event Reporting, and Clinical Trial Design. Neuman HB. J Clin Oncol. October 2023
  • Podcast – JCO Article Insights: Low and Moderate Grade Adverse Events and the Patient Experience in Clinical Trials. Listen on Spotify or wherever you get your podcasts.
• Symptom Science and Treatment Toxicity – Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients with Renal Cell Carcinoma and Thyroid Cancer Treated with VEGFR TKIs. Narayan VK. J Natl Compr Canc Netw. October 2023